athological mechanisms and disease progression of multiple sclerosis:therapeutic implication(多发性硬化症的病理机 制和病程进展：治疗意义）Drugs of Today.38:7-29. 阳266] 3.化exetal.(200リ"Alongi1:udinals1:udyof油no;rmalitiesonMRIand dis油ility from multiple scle;rosis(MRI崎形和多发性硬化症残疾的纵向研究）"，N Engl TMed. Jan 17, 2002：M6 (3) : 158-64.
[0267] 4. Bruck et al. (2012) "Reduced astrocytic NF-kappaB activation bylaquinimodprotectsfromcuprizone-induceddemyelination(通 过控唾 莫德降化的星形细胞NF-kB活化作用免受环己酬二腺诱导的脱髓革肖）"，Acta Neuropathol. 124:411-424.
[0268] 5.Brunmarketal. (2002)"Theneworallyactiveimmunoregulator laquinimod(AB民-215062)effectivelyinhibitsdevelopmentandrelapsesof experimentalautoimmuneencephalomyelitis(新口 服活性免疫调节剂控唾莫德 (ABR-215062)有效抑制实验性自身免疫性脑脊髓炎）TNeuroimmunology. 130:163-172.
[0269] 6.Cohenetal. (2010)，，Oralfingolimodorintramuscularinterferonfor relapsingmultiplesclerosis(用于复发型多发性硬化症的口服芬戈莫德或肌肉注射干 扰素），，?NEngTMed：362:402-415.
[0270] 7.Comietal. (2007)LAQ/5062StudyGroup."TheEffectofTwo DosesofLaquinimodonM民I-MonitoredDiseaseActivityinPatientswith 民elapsing-民emittingMultipleSclerosis:AMulti-Center,民andomized,Double-Blind ，Placebo-Controlledstudy(两种剂量拉哇莫德对于具有复发缓解型多发性硬化症的患 者中MRI监控的疾病活动度的作用：多中屯、、随机、双盲、安慰剂对照研究）"，Presented at:59thAnnualMeetingoftheAmericanAcademyofNeurology；April28 _May 5, 2007 ;Boston,M.
[027。 8.Comietal. (2008)"EffectoflaquinimodonMRI-monitoreddisease activityinpatientswithrelapsing-remittingmultiplesclerosis:amulticentr e,randomised,double-blind,placebo-controlledphasenbs化dy(控唾莫德对于具有 复发缓解型多发性硬化症的患者中MRI监控的疾病活动度的作用：多中屯、、随机、双盲、安 慰剂对照 1化期研究）"、Lancet. 371:2085-2092.
[0272] 9.Comietal. (2009)for化eLAQ/5062ClinicalAdvisoryBoardandS化dy Group.Long-termopenextensionoforallaquinimodinpatientswithrelapsing multiplesclerosisshowsfavorablesafetyandsustainedlowrelapserateand MRIactivity(具有复发缓解型多发性硬化症的患者中口服控唾莫德的长期开放扩展显 示了良好的安全性和持久的化复发率及MRI活动度）?圧ctrimsabstractP443l.Mult Scler. 15(Suppl2) :S127.
[0273] 10.Comietal. (2010)fortheLAQ/5062ClinicalAdvisoryBoardandS化dy Group.TheeffectoflaquinimodonM民I-monitoreddiseaseactivityinpatients withrelapsing-remittingmultiplesclerosis:adouble-blindactiveextension ofthemulticentre，randomised，double-blind，parallel-groupplacebo-controlled study(拉哇莫德对于具有复发缓解型多发性硬化症的患者中MRI监控的疾病活动度的作 用:《中屯、、随柄,、双盲、平行紀安尉剂对照研究）.MultScler. 16:1360-1366.
[0274] 11.Cutteretal. (1999) "Developmentofamultiplesclerosisfunctional compositeasaclinicaltrialoutcomemeasure(多发性硬化症功能复合作为临床试验 疗效测量的发展）"，Brain. 122:871-882.
[02"7日]12.DeStefanoetal. (1999)"Evidenceofearlyaxonaldamagein patientswithmultiplesclerosis(具有多发性硬化症的患者中早期轴突损伤的证 据)"，Neurology. 52 (Suppl 2) :A378.
[0276]IS.Dunitz.M. (1999)Multiple sclerosistherapeutics(多发性硬化痛治 疗），Ed. Rudick and Goodkin. London:T过ylor&Pr过ncis，1999.
[0277] 14. Durelli et al. and the Independent Comparison of Interferon(INCOMIN) Trial Study Group. (2002)"Every-〇ther-day interferon beta-lb versus once-weekly interferon beta-la for multiple sclerosis:results of a 2-year prospective randomised multicentre s化dy(INCOMIN)(对于多发性硬化症每隔一天干扰素化对于 每周一次干扰素P-la :2年预期随机多中屯、研究(INCOMIN)) ".Lancet. 359:1453-60.
[0278] 15. EMEA Guideline on Clinical Investigation of Medicinal Products for 化e Treatment of Multiple Sclerosis(对于多发性硬化症治疗的医学产品的临床调查的 EMEA指南）（CPMP/EWP/561/98Rev. 1，Nove. 2006).
[0279] 16. Fischer et al. (1999) "llie Multiple Sclerosis F'unctional Composite measure(MSFC) :an integrated approach to MS clinical outcome assessment(多 发性硬化症功能复合测量（MSFC):对于MS临床疗效评估的综合方法）"Multiple Sclerosis. 5 (4) : 244-250.
[0280] 17?門sk et al. (1994)"Measuring化e Functional Impact of Fatigue: Initial Validation of Fatigue Impact Scale(测量疲劳的功能影响：疲劳影响量表的初步验 证）"，Clin Inf Pis. 18 Suppl l:S79-83.
[02别] 18. Fisk et al. (1994) "Hie Impact of Fatigue on Patients with Multiple Sclerosis (疲劳对于具有多发性硬化症患者的影响）"，Can T Neurol Sci. 21:9-14.
[028引 19. Rrohman et al. (2003) "Hie utility of MRI in suspected MS:r邱OTt of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology(MRI在疑似MS中的应用：美国神经学会治疗和技术评估附属委员会报 告）".Neurology. Sep 9, 2003, 61 (5) :602_1L
[0283] 20. Giovannoni et al. (2010) "A placebo-controlled trial of oral cladr;Lbine for relapsing multiple sclerosis(用于复发型多发性硬化症口服克控曲滨 的安慰剂对照试验）"，N Eng T Med. 362:416-426.
[0284] 21.Golder W. (2007) "Magnetic resonance spectroscopy in clinical oncology (临床肿瘤学中磁共振波谱学）"、0nkol〇gie. 27(3) : 304-9.
[028己] 22. Grossman et al. (1994)Magnetization transfer:theory and clinical applications in neuroradiology (磁化转移:在神经放射学中巧论和临庆应用）"，Ra化oGraphics. 14:279-290.
[0286] 23. Gurevich et al. (2010) "Laqui打imod suppress antigen presentation in relapsing-remitting multiple sclerosis:in-vitro high-throughput gene expression study (控唾莫德抑制复发缓解型多发性硬化症中的抗原表达：体外高通量基 因表达研究）"，J Neuroimmunol. 221:87_94.
[0287] 24. Hartung et al. (2005) "Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis:expert opinions based on the Proceedi打gs of过打I打ter打过tio打过1 Consensus Conference (it、^^^；^于生石更"[七5!^ 期间对于干扰素P的中和抗体的電要性：基于国际共巧会议会议录的专家意化Eur TNeurol. 12:588-601.
[0288] 25. Hauser et al. (1983) "Intensive immunosuppression in progressive multiple sclerosis (在进展型多发性硬化症中的加强免疫抑制）"，New Engl J Med. 308:173-180.
[0289] 26. Hawker et al. (2009) "RiUuximab in Patients w;Uh Primary Progressive Multiple Sclerosis -民esults of a Randomized Double-Blind Placebo-Controlled Multicenter化ial(在具有原发进展型多发性硬化症的患者中利妥昔单抗一随机、双盲、 安慰剂对照、多中屯、试验的结果）"，Ann Neurol，66:460-471.
[0290] 27. Hohlfeld et al. (2000) "The neuroprotective effect of inf lamination: implications for the therapy of multiple sclerosis(炎症的神经保护 作用:对于多发性硬化痛治疗的启示）"，J Neuroimmunol. 107:161-166.
[02W] 28. Humphries (2012)叩regressive multiple sclerosis:Hie treatment gap(进 展型多发性硬化症：治疗差距）"、Na化re、484 (S10)，doi : 10. 1038/nature 11108.
[0292] 29. Jacobs et al. (1996) ^ Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis(对于复发型多发性硬化症中病程进展肌 肉注射干扰素P -la) "，Ann Neurol. 39:285-294.
[0293] 30.Kappos et al. (2010) "A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis(在复发型多发性硬化症中口服芬戈莫德的安慰剂对 照试验）"，N Eng T Med. 362:387-401.
[0294] 31.Kurtzke JF. (1983) "Rating neurologic impairment in multiple sclerosis:an expanded disability status scale(邸SS)(评级多发性硬化症中的神经损 伤：扩展残疾状态量表化DSS))".Neurology33 (11) : 1444-1452.
[02巧]32.La Mantia et al. (2012) "Interferon 0 for secondary progre